Antidepressant dose matters for seniors with weak kidneys

NCT ID NCT07274241

First seen Jan 03, 2026 · Last updated Jun 21, 2026 · Updated 26 times

Summary

This study looked at over 12,000 older adults (age 66+) with low kidney function who started taking the antidepressant escitalopram. It compared the safety of a 10 mg daily dose versus a 5 mg daily dose. The goal was to see if the higher dose led to more hospital visits or deaths within 30 days. The findings could help guide safer prescribing for this vulnerable group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • London Health Sciences Centre Research Institute

    London, Ontario, Canada

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Escitalopram (antidepressant) at 5 or 10 mg/day

What this could lead to

If it finds a safer dose, it could help doctors prescribe escitalopram more safely for older adults with kidney problems.

What could go wrong

This is an observational study, not a controlled trial, so it can only show links, not cause and effect. Results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.